Effect of Intravenous Continuous Infusion Heparin on Rates of Venous Thromboembolism in High-Risk, Critically Ill Patients

Withdrawn before enrolling · Not applicable

Conditions studied: Venous Thromboembolism

In brief

The primary purpose of this study is to demonstrate that a continuous infusion of intravenous (IV) heparin (UFH) for Venous thromboembolism (VTE) prophylaxis will restore prophylactic levels of heparin in high-risk critically ill medical patients as compared with guideline recommended subcutaneous heparin. Antifactor Xa assay, a laboratory test to measure the anticoagulant activity of heparin, or the ability of heparin to thin the blood, will be used to demonstrate that Intravenous administration is more effective.

Key facts

Study ID

NCT02707263

Run by

NYU Langone Health

People needed

0

Starts

2016-03-01

Expected to finish

2017-04-01

Last updated by the study team

2017-04-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Admission to the medical ICU (MICU)
• High-risk for Venous Thromboembolism (VTE) ≥ 1 of the following:
• Body Mass Index (BMI) ≥ 30 kg/m2
• Personal or family history of VTE
• Receiving vasopressors

You may not qualify if…

• Indication for therapeutic anticoagulation
• Evidence of deep vein thrombosis (DVT) on ultrasonography at admission
• Indwelling intrathecal, epidural, or other indwelling deep catheters
• Recent (< 3 months) International Society of Thrombosis and Haemostasis (ISTH) major bleeding13
• Recent (< 3 months) major trauma
• Recent (< 3 months) neurosurgery or orthopedic surgery Pregnancy
• Contraindication to heparin or heparin products

Where it is running

• New York University School of Medicine — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.